OSI hires GSK’s Ingram
Executive Summary
GlaxoSmithKline Vice Chairman-Pharmaceuticals Robert Ingram joins OSI Pharmaceuticals as chairman of board of directors in a non-executive capacity, effective Jan. 1. "Ingram will assume chairmanship of the Board's executive, nominating and compensation committees," OSI said. OSI CEO Colin Goddard relinquishes chairmanship of board. Ingram retired as GSK chief operating officer and pharmaceutical operations president in December (1"The Pink Sheet" Oct. 21, 2002, p. 27)...
You may also be interested in...
Valeant Chairman Robert O’Leary
Valeant Chairman Robert O'Leary died at the age of 62 following a long battle with cancer, company announces Aug. 14. Board elects GlaxoSmithKline Vice Chairman-Pharmaceuticals Robert Ingram, a member of Valeant's board since 2003, to serve as chairman. Ingram has also chaired OSI Pharmaceutical's board since 2003 (1"The Pink Sheet" Jan. 13, 2003, In Brief)...
GSK’s Ingram joins Allergan’s board
GlaxoSmithKline Vice Chairman-Pharmaceuticals Bob Ingram is joining Allergan's board of directors. He sits on the board of several corporations, including Edwards Lifesciences and Lowe's, as well as serving as chairman of the board of OSI Pharmaceuticals (1"The Pink Sheet" Jan. 13, 2003, In Brief). Ingram's relationship with Allergan is somewhat noteworthy as both Allergan and GSK are members of the Pharmaceutical Research & Manufacturers of America...
GSK Management Triangle: Viehbacher To Head U.S. Rx, Reporting To Stout
GlaxoSmithKline is keeping its Research Triangle Park, N.C. operational center under new U.S. Pharmaceuticals President Christopher Viehbacher